TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Surgical Treatment of Long Occlusions of the Superficial Femoral Artery: Initial Success and Long Term Results of Remote Endarterectomy Versus Suprageniculate Bypass Surgery
Brief Summary: The objective of this study is to compare remote superficial femoral artery endarterectomy with suprageniculate bypass surgery in the treatment of long occlusions of the superficial femoral artery. The study hypothesis is that patency rates are comparable and therefore the minimal invasive remote superficial femoral artery endarterectomy can be considered in patients presenting with a long occlusion of the superficial femoral artery.


Options:
A: Arm Label: Drug-eluting balloon; Type: EXPERIMENTAL; Interventions: Device: Cotavance Drug-Eluting Balloon | Arm Label: Plaque excision + drug-eluting balloon; Type: EXPERIMENTAL; Interventions: Device: TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon | Arm Label: Severely Ca++ Group; Type: EXPERIMENTAL; Interventions: Device: TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon | Intervention Type: DEVICE; Name: Cotavance Drug-Eluting Balloon; Assigned to Arm(s): Drug-eluting balloon | Intervention Type: DEVICE; Name: TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon; Assigned to Arm(s): Plaque excision + drug-eluting balloon | Intervention Type: DEVICE; Name: TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon; Assigned to Arm(s): Severely Ca++ Group
B: Arm Label: Laser atherectomy and PTA; Type: EXPERIMENTAL; Interventions: Device: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters | Arm Label: Balloon angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Balloon angioplasty | Intervention Type: DEVICE; Name: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters; Assigned to Arm(s): Laser atherectomy and PTA | Intervention Type: PROCEDURE; Name: Balloon angioplasty; Assigned to Arm(s): Balloon angioplasty
C: Arm Label: REA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote endarterectomy of the superficial femoral artery | Arm Label: Bypass; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Suprageniculate femoropopliteal bypass | Intervention Type: PROCEDURE; Name: Remote endarterectomy of the superficial femoral artery; Assigned to Arm(s): REA | Intervention Type: PROCEDURE; Name: Suprageniculate femoropopliteal bypass; Assigned to Arm(s): Bypass
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: PTA with placement of paclitaxel-eluting stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA | Intervention Type: DEVICE; Name: PTA with placement of paclitaxel-eluting stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: PTA; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Surgical Treatment of Long Occlusions of the Superficial Femoral Artery: Initial Success and Long Term Results of Remote Endarterectomy Versus Suprageniculate Bypass Surgery
Brief Summary: The objective of this study is to compare remote superficial femoral artery endarterectomy with suprageniculate bypass surgery in the treatment of long occlusions of the superficial femoral artery. The study hypothesis is that patency rates are comparable and therefore the minimal invasive remote superficial femoral artery endarterectomy can be considered in patients presenting with a long occlusion of the superficial femoral artery.


Options:
A: Arm Label: Heparin-bonded endoluminal fempop bypass; Type: EXPERIMENTAL; Interventions: Procedure: Heparin-bonded ePTFE endoluminal fem-pop bypass | Arm Label: Surgical femoro-popliteal bypass; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgical femoro-popliteal bypass. | Intervention Type: PROCEDURE; Name: Heparin-bonded ePTFE endoluminal fem-pop bypass; Assigned to Arm(s): Heparin-bonded endoluminal fempop bypass | Intervention Type: PROCEDURE; Name: Surgical femoro-popliteal bypass.; Assigned to Arm(s): Surgical femoro-popliteal bypass
B: Arm Label: REA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote endarterectomy of the superficial femoral artery | Arm Label: Bypass; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Suprageniculate femoropopliteal bypass | Intervention Type: PROCEDURE; Name: Remote endarterectomy of the superficial femoral artery; Assigned to Arm(s): REA | Intervention Type: PROCEDURE; Name: Suprageniculate femoropopliteal bypass; Assigned to Arm(s): Bypass
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Therapy, Drug: Cilostazol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Drug: Cilostazol | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Behavioral: Supervised Exercise Therapy | Intervention Type: DEVICE; Name: Stent; Assigned to Arm(s): 2, 3 | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Therapy; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): 1, 2
D: Arm Label: Open Bypass Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open Bypass Surgery | Arm Label: Angioplasty and Stenting; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Angioplasty and Stenting | Intervention Type: PROCEDURE; Name: Open Bypass Surgery; Assigned to Arm(s): Open Bypass Surgery | Intervention Type: PROCEDURE; Name: Angioplasty and Stenting; Assigned to Arm(s): Angioplasty and Stenting

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: School Centered Telemedicine Program for Children With Type 1 Diabetes Mellitus
Brief Summary: The purpose of this study is to determine if using school-based telemedicine for diabetes support and education in students with type 1 diabetes in grades K-8 can lead to improvement in control of diabetes and improved satisfaction of all caregivers.


Options:
A: Arm Label: A, 1, I; Type: EXPERIMENTAL; Interventions: Device: Home blood pressure tele-management system. | Arm Label: A, 2, I; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care. | Intervention Type: DEVICE; Name: Home blood pressure tele-management system.; Assigned to Arm(s): A, 1, I | Intervention Type: OTHER; Name: Usual care.; Assigned to Arm(s): A, 2, I
B: Arm Label: Enhanced Internet-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored content, Behavioral: Generic Internet-based information, Behavioral: Discussion forum, Behavioral: Behavioral monitoring | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic Internet-based information, Behavioral: Discussion forum | Intervention Type: BEHAVIORAL; Name: Tailored content; Assigned to Arm(s): Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Generic Internet-based information; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Discussion forum; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Behavioral monitoring; Assigned to Arm(s): Enhanced Internet-based intervention
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: telemedicine | Intervention Type: OTHER; Name: telemedicine; Assigned to Arm(s): 2
D: Arm Label: Telemedicine; Type: N/A; Interventions: N/A | Arm Label: Telephone; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind Placebo-Controlled Parallel Group Study of the Efficacy and Safety of XRP0038/NV1FGF on Amputation or Any Death in Critical Limb Ischemia Patients With Skin Lesions
Brief Summary: Primary objective is to demonstrate the superiority of riferminogene pecaplasmid (XRP0038/NV1FGF) over placebo in the prevention of major amputation above the ankle of the treated leg or of death from any cause, whichever comes first, in critical limb ischemia (CLI) patients with skin lesions.

Secondary objectives are to evaluate:

* The efficacy of riferminogene pecaplasmid versus placebo for delaying the time to major amputation;
* The efficacy of riferminogene pecaplasmid versus placebo for delaying the time to death;
* The safety of riferminogene pecaplasmid in the study population.


Options:
A: Arm Label: BM-MNC; Type: EXPERIMENTAL; Interventions: Procedure: BM-MNC preparation | Arm Label: PB-MNC; Type: EXPERIMENTAL; Interventions: Procedure: PB-MNC preparation | Intervention Type: PROCEDURE; Name: BM-MNC preparation; Assigned to Arm(s): BM-MNC | Intervention Type: PROCEDURE; Name: PB-MNC preparation; Assigned to Arm(s): PB-MNC
B: Arm Label: Riferminogene pecaplasmid; Type: EXPERIMENTAL; Interventions: Biological: riferminogene pecaplasmid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo (for riferminogene pecaplasmid) | Intervention Type: BIOLOGICAL; Name: riferminogene pecaplasmid; Assigned to Arm(s): Riferminogene pecaplasmid | Intervention Type: BIOLOGICAL; Name: Placebo (for riferminogene pecaplasmid); Assigned to Arm(s): Placebo
C: Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: bone marrow stem cells intraarterial; Type: ACTIVE_COMPARATOR; Interventions: Biological: bone marrow stem cells (BMC) | Arm Label: tissue repair cells intramuscular; Type: ACTIVE_COMPARATOR; Interventions: Biological: tissue repair cells (TRC) | Arm Label: tissue repair cells intraarterial; Type: ACTIVE_COMPARATOR; Interventions: Biological: tissue repair cells (TRC) | Arm Label: bone marrow stem cells intramuscular; Type: ACTIVE_COMPARATOR; Interventions: Biological: bone marrow stem cells (BMC) | Intervention Type: BIOLOGICAL; Name: tissue repair cells (TRC); Assigned to Arm(s): tissue repair cells intraarterial, tissue repair cells intramuscular | Intervention Type: BIOLOGICAL; Name: bone marrow stem cells (BMC); Assigned to Arm(s): bone marrow stem cells intraarterial, bone marrow stem cells intramuscular
D: Arm Label: becaplermin gel; Type: EXPERIMENTAL; Interventions: Drug: becaplermin gel | Arm Label: Duoderm Hydrogel™; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duoderm Hydrogel™ | Intervention Type: DRUG; Name: becaplermin gel; Assigned to Arm(s): becaplermin gel | Intervention Type: DRUG; Name: Duoderm Hydrogel™; Assigned to Arm(s): Duoderm Hydrogel™

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind Placebo-Controlled Parallel Group Study of the Efficacy and Safety of XRP0038/NV1FGF on Amputation or Any Death in Critical Limb Ischemia Patients With Skin Lesions
Brief Summary: Primary objective is to demonstrate the superiority of riferminogene pecaplasmid (XRP0038/NV1FGF) over placebo in the prevention of major amputation above the ankle of the treated leg or of death from any cause, whichever comes first, in critical limb ischemia (CLI) patients with skin lesions.

Secondary objectives are to evaluate:

* The efficacy of riferminogene pecaplasmid versus placebo for delaying the time to major amputation;
* The efficacy of riferminogene pecaplasmid versus placebo for delaying the time to death;
* The safety of riferminogene pecaplasmid in the study population.


Options:
A: Arm Label: Neovasculgen®; Type: EXPERIMENTAL; Interventions: Drug: Neovasculgen® | Arm Label: standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Neovasculgen® | Intervention Type: DRUG; Name: Neovasculgen®; Assigned to Arm(s): Neovasculgen®, standard care
B: Arm Label: NV1FGF 500 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 2000 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 4000 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): NV1FGF 2000 μg, NV1FGF 4000 μg, NV1FGF 500 μg
C: Arm Label: Riferminogene pecaplasmid; Type: EXPERIMENTAL; Interventions: Biological: riferminogene pecaplasmid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo (for riferminogene pecaplasmid) | Intervention Type: BIOLOGICAL; Name: riferminogene pecaplasmid; Assigned to Arm(s): Riferminogene pecaplasmid | Intervention Type: BIOLOGICAL; Name: Placebo (for riferminogene pecaplasmid); Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Genetic: HGF plasmid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Genetic: HGF plasmid | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Genetic: HGF plasmid | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Genetic: HGF plasmid | Intervention Type: GENETIC; Name: HGF plasmid; Assigned to Arm(s): 1, 2, 3, 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial: a Randomized Evaluation of First-dollar Coverage for Post-MI Secondary Preventive Therapies
Brief Summary: The objective of this randomized trial is to evaluate the effect of providing full prescription drug coverage (i.e. no co-pays, co-insurance or deductibles) for statins, beta-blockers, angiotensin converting enzyme inhibitors and angiotensin II receptor blockers to patients recently discharged from hospital after acute myocardial infarction.


Options:
A: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Basic medication therapy management; Type: EXPERIMENTAL; Interventions: Behavioral: Basic medication therapy management | Arm Label: Enhanced medication therapy management; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced medication therapy management | Intervention Type: BEHAVIORAL; Name: Basic medication therapy management; Assigned to Arm(s): Basic medication therapy management | Intervention Type: BEHAVIORAL; Name: Enhanced medication therapy management; Assigned to Arm(s): Enhanced medication therapy management
B: Arm Label: Care Management+Community Health Worker; Type: EXPERIMENTAL; Interventions: Behavioral: Care Management+Community Health Worker | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Care Management+Community Health Worker; Assigned to Arm(s): Care Management+Community Health Worker | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Medication therapy management; Type: EXPERIMENTAL; Interventions: Other: Medication therapy management | Intervention Type: OTHER; Name: Medication therapy management; Assigned to Arm(s): Medication therapy management
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Full drug coverage | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual coverage | Intervention Type: OTHER; Name: Full drug coverage; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Usual coverage; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial: a Randomized Evaluation of First-dollar Coverage for Post-MI Secondary Preventive Therapies
Brief Summary: The objective of this randomized trial is to evaluate the effect of providing full prescription drug coverage (i.e. no co-pays, co-insurance or deductibles) for statins, beta-blockers, angiotensin converting enzyme inhibitors and angiotensin II receptor blockers to patients recently discharged from hospital after acute myocardial infarction.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Full drug coverage | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual coverage | Intervention Type: OTHER; Name: Full drug coverage; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Usual coverage; Assigned to Arm(s): 2
B: Arm Label: FDC Fixed Dose Combination; Type: EXPERIMENTAL; Interventions: Drug: FDC | Arm Label: Conventional treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Separately drugs, simvastatin, aspirin and ramipril | Intervention Type: DRUG; Name: FDC; Assigned to Arm(s): FDC Fixed Dose Combination | Intervention Type: DRUG; Name: Separately drugs, simvastatin, aspirin and ramipril; Assigned to Arm(s): Conventional treatment
C: Intervention Type: BEHAVIORAL; Name: Comprehensive pharmacy care program; Assigned to Arm(s): N/A
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Arm 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial: a Randomized Evaluation of First-dollar Coverage for Post-MI Secondary Preventive Therapies
Brief Summary: The objective of this randomized trial is to evaluate the effect of providing full prescription drug coverage (i.e. no co-pays, co-insurance or deductibles) for statins, beta-blockers, angiotensin converting enzyme inhibitors and angiotensin II receptor blockers to patients recently discharged from hospital after acute myocardial infarction.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Text messaging reminders | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Text messaging reminders; Assigned to Arm(s): 1
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Full drug coverage | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual coverage | Intervention Type: OTHER; Name: Full drug coverage; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Usual coverage; Assigned to Arm(s): 2
C: Intervention Type: BEHAVIORAL; Name: Shared Decision-Making; Assigned to Arm(s): N/A
D: Arm Label: Reciprocal Diabetes Peer Support program; Type: EXPERIMENTAL; Interventions: Behavioral: Reciprocal Diabetes Peer Support Program, Behavioral: group outpatient counseling visits | Arm Label: Nurse Case Management; Type: OTHER; Interventions: Behavioral: Nurse Case management | Intervention Type: BEHAVIORAL; Name: Reciprocal Diabetes Peer Support Program; Assigned to Arm(s): Reciprocal Diabetes Peer Support program | Intervention Type: BEHAVIORAL; Name: Nurse Case management; Assigned to Arm(s): Nurse Case Management | Intervention Type: BEHAVIORAL; Name: group outpatient counseling visits; Assigned to Arm(s): Reciprocal Diabetes Peer Support program

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Comparison of Thoracoscopic Lung Volume Reduction Surgery Performed by Resectional Surgical Technique Under General Anesthesia or by a Non-Resectional Technique in Awake Patients Under Sole Epidural Anesthesia
Brief Summary: Lung volume reduction surgery is effective in improving pulmonary function and quality of life in selected patients with severe emphysema although the morbidity of this surgical procedure is still considerable. Morbidity is mainly addressed to general anesthesia-related adverse effects and surgical trauma deriving from lung resection. Having developed an awake nonresectional lung volume reduction surgery technique, which is performed under sole thoracic epidural anesthesia, we have hypothesized that it could offer satisfactory clinical results and reduced morbidity rate when compared with the conventional surgical procedure.


Options:
A: Arm Label: BTVA; Type: EXPERIMENTAL; Interventions: Device: BTVA System | Intervention Type: DEVICE; Name: BTVA System; Assigned to Arm(s): BTVA
B: Intervention Type: PROCEDURE; Name: Lung volume reduction surgery; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: awake nonresectional LVRS | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Nonawake resectional LVRS | Intervention Type: PROCEDURE; Name: awake nonresectional LVRS; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Nonawake resectional LVRS; Assigned to Arm(s): 2
D: Intervention Type: DEVICE; Name: AeriSeal System; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Comparison of Thoracoscopic Lung Volume Reduction Surgery Performed by Resectional Surgical Technique Under General Anesthesia or by a Non-Resectional Technique in Awake Patients Under Sole Epidural Anesthesia
Brief Summary: Lung volume reduction surgery is effective in improving pulmonary function and quality of life in selected patients with severe emphysema although the morbidity of this surgical procedure is still considerable. Morbidity is mainly addressed to general anesthesia-related adverse effects and surgical trauma deriving from lung resection. Having developed an awake nonresectional lung volume reduction surgery technique, which is performed under sole thoracic epidural anesthesia, we have hypothesized that it could offer satisfactory clinical results and reduced morbidity rate when compared with the conventional surgical procedure.


Options:
A: Arm Label: Lung Volume Reduction Coil (LVRC); Type: EXPERIMENTAL; Interventions: Device: Lung Volume Reduction Coil (LVRC) (PneumRx) | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Device: Control | Intervention Type: DEVICE; Name: Lung Volume Reduction Coil (LVRC) (PneumRx); Assigned to Arm(s): Lung Volume Reduction Coil (LVRC) | Intervention Type: DEVICE; Name: Control; Assigned to Arm(s): Control
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: awake nonresectional LVRS | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Nonawake resectional LVRS | Intervention Type: PROCEDURE; Name: awake nonresectional LVRS; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Nonawake resectional LVRS; Assigned to Arm(s): 2
C: Arm Label: Lung volume reduction surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lung volume reduction surgery | Arm Label: No lung volume reduction surgery; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Lung volume reduction surgery; Assigned to Arm(s): Lung volume reduction surgery
D: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel | Intervention Type: DRUG; Name: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel; Assigned to Arm(s): Group 1, Group 2

Answer: B